I'd not like to play backgammon, I remember reading your post saying you were once a ranked player. Would you happen to know Bill Cadger?
I'm looking at this from a different angle. If genr doesn't have an approvable drug for whatever reason, systemic tox, efficacy, then what does it matter? I don't think macugen, retaane or visudyne are cure all end all's in amd. So imo there's still plenty of room for a breakthrough AMD therapy.
However, if genr or another possible AMD play I like develops a clearly superior drug, with durable responses, I think this is a highly educated space that will be eager to switch. So imo seeing pfe and its minions helping build up the market with what seems to be an OK, not great drug, is a good thing for genr or others with differentiated approaches.
Market Data 
Markets 
AI
